Free
Meeting Abstracts  |   July 1998
Flow-induced Dilation of Rat Coronary Microvessels Is Attenuated by Isoflurane but Enhanced by Halothane 
Author Notes
  • (Park) Assistant Professor of Anaesthesia, Department of Anesthesia and Critical Care.
  • (Dai) Research Fellow, Department of Surgery.
  • (Lowenstein) Professor of Anaesthesia, Department of Anesthesia and Critical Care.
  • (Sellke) Associate Professor of Surgery, Department of Surgery.
Article Information
Meeting Abstracts   |   July 1998
Flow-induced Dilation of Rat Coronary Microvessels Is Attenuated by Isoflurane but Enhanced by Halothane 
Anesthesiology 7 1998, Vol.89, 132-142. doi:
Anesthesiology 7 1998, Vol.89, 132-142. doi:
FLOW-INDUCED dilation (FID) is one of the determinants of myocardial blood flow distribution, along with metabolic, myogenic, and neurohumoral influences. [1] When flow increases in a coronary vessel, the resulting increase in shear stress on the endothelium leads to the production of endothelium-derived relaxing factor(s). [2] Although metabolic control may be primarily responsible for the close matching of coronary blood flow to tissue needs, myogenic and endothelial regulatory mechanisms play synergistic roles via transduction of intravascular pressure and flow, respectively. [1] 
Volatile anesthetics attenuate agonist-mediated endothelium-dependent vasodilation (EDD) of both conductance [3,4] and resistance arteries [5,6] in vitro and of pulmonary vessels in vivo. [7] Further, the hemodynamic effect of nitric oxide (NO) synthase inhibitors is less during halothane anesthesia than during the awake state, suggesting that the unstimulated EDD is less with halothane. [8] Although isoflurane and halothane both attenuate EDD, the sites of anesthetic action in the NO-cyclic guanosine monophosphate (NO-cGMP) pathway may be different, depending on the anesthetic, the vessel type, and perhaps experimental conditions. [4,5,9–12] 
In this study, we examined the effect of volatile anesthetics on another type of EDD, namely FID. We studied changes in pressure gradient across isolated coronary resistance arteries while keeping the intravascular pressure constant to remove any myogenic effects. Changes in pressure gradient produce changes in flow in and shear stress on the vessel. We considered whether vasomotion produced by changes in pressure gradient and flow was endothelium dependent by studying the effect of endothelial denudation, the NO synthase inhibitor NG-nitro-L-arginine(L-NNA), the NO scavenger hemoglobin, and the cyclooxygenase inhibitor indomethacin. We examined the effect of the volatile anesthetics isoflurane and halothane on FID, in the presence of LNNA, indomethacin, or neither one. Because, in our previously study with the NO-cGMP pathway in rat resistance coronary arteries, [5] halothane had no effect distal to the agonist receptor whereas isoflurane did, we hypothesized that isoflurane may have an attenuating effect on FID but halothane may not.
Methods
Vessel Preparation
In accordance with institutional animal care committee standards, Wistar rats of either sex that weighed 100–150 g were anesthetized by injecting 40 mg/kg ketamine and 5 mg/kg xylazine intraperitoneally. Subepicardial microvessels that were third- or fourth-order branches of the left anterior descending artery were prepared as described previously. [13] Each vessel was placed in a vessel chamber, cannulated with dual micro-pipettes (50 - 70 [micro sign]m), and secured with 10–0 Ethilon (Ethicon Inc., Somerville, NJ) sutures. To ensure uniformity of size and thus resistance offered by the pipettes, each pipette was prepared using Narishige automatic pipette maker (Narishige Scientific Instrument Laboratory, Tokyo, Japan) at constant settings and matched for size under the microscope on both sides of a vessel. The pipettes were connected with silicone tubing to columns of fluids to provide a distending pressure in the vessel. The system was arranged symmetrically so that the vessel represented the midpoint. By varying the heights of the columns of fluids simultaneously and equally in opposite directions, we could vary the pressure gradient (Delta P) and, therefore, flow across the vessel, while maintaining the midpoint intravascular pressure constant. [14,15] In seven vessels the actual midpoint intravascular pressure was 40 +/- 2 mmHg (mean +/- SD), as the pressure gradient was varied from 0 to 80 mmHg and the mean of the upstream and downstream pressures was held constant at 40 mmHg. In another preliminary study, symmetry of the setup was further verified by measuring FID in four microvessels with flow in one direction and then in the reverse direction (in random order) and noting no significant difference in FID with changes in the direction of flow.
The vessel was bathed continuously with modified Krebs buffer (120 mM NaCl, 5.9 mM KCl, 11.1 mM dextrose, 25 mM NaHCO3, 1.2 mM NaH2PO (4), 1.2 mM MgSO4, and 2.5 mM CaCl2), gassed with a 95% oxygen and 5% carbon dioxideemixture, and maintained at 37 [degree sign]C and pH 7.4. The oxygen tension (PO(2)) in the vessel chamber exceeded 400 mmHg.
Direct proportionality between Delta P and flow in an in vitro preparation such as ours was shown before. [15] In a preliminary study, to confirm that production of Delta P was associated also with proportional changes in flow in our experimental preparation, we measured flow across six control vessels at Delta P values of 20, 40, 60, and 80 mmHg by collecting the effluent for a period of 1 h and measuring the weight of the fluid collected. (The density of Krebs solution at 37 [degree sign]C was 1.018 g/ml.) The flows were 77 +/- 11 nl/s, 134 +/- 17 nl/s, 194 +/- 13 nl/s, and 233 +/- 17 nl/s at Delta P values of 20, 40, 60, and 80 mmHg, respectively. There was a linear relation between Delta P and flow (correlation coefficient [r]= 0.97, P < 0.001). The flows in our preparation were greater than the flows in the preparation used by Kuo et al. [15] but of the same order of magnitude.
The vessel was visualized with an inverted phase-contrast microscope (Olympus IMT-2, Tokyo, Japan) connected to a video camera. The vessel image was projected onto a television screen (Panasonic, Osaka, Japan). The vessel internal lumen diameter was measured using an optical density video detection system (Living Systems Instrumentation, Burlington, VT). [13] Measurements of the lumen diameter were recorded with a Western Graphtec Multicorder (Irvine, CA). The stability of both endothelium-intact and endothelium-denuded vessels in our experimental preparation for at least 2.5 h was shown previously. [16] Schematics of our [13] and similar [14,15] preparations have been published already.
Measurement of Flow-induced Vasodilation
Each vessel was equilibrated in the vessel chamber at 37 [degree sign]C with an intraluminal pressure of 40 mmHg and Delta P of 0 mmHg for 30 min. After measurement of the baseline internal diameter (Dbaseline), the vessel was preconstricted with 1 [micro sign]M of the thromboxane analog U46619 for 5 min and the constricted diameter (Dconst) was measured. Delta P was increased from 0 to 80 mmHg in 10-mmHg increments while the midpoint intraluminal pressure constant was maintained at 40 mmHg. In a preliminary experiment with six rat coronary arteries, no hysteresis was observed. We found that the Delta P-diameter relation obtained with Delta P increments from 0 to 80 mmHg could be superimposed on the relation obtained with Delta P decrements from 80 to 0 mmHg. Therefore, in the current study, all measurements were obtained during Delta P increments only.
At each pressure gradient the vessel was allowed to reach a steady state diameter for 3 min and then the steady state diameter was recorded (D (relax)). The percentage relaxation from preconstriction with U46619 was calculated as:Equation 1At the end of each vessel run, the Delta P was returned to 0 mmHg and the vessel was flushed with fresh Krebs buffer and reequilibrated at 37 [degree sign]C. Potassium chloride was added to a final concentration of 100 mM, followed by 10 [micro sign]M of the endothelium-dependent dilator adenosine diphosphate. Only those vessels that constricted to potassium chloride by 15% or more were considered still viable [16] and included for data analysis. Preservation of endothelial function was assessed by the vessel response to adenosine diphosphate.
Similar studies were performed with the intraluminal pressure kept at 20 or 60 mmHg. Because flow-mediated dilation was maximal at 40 mmHg (Figure 1) and this is in the physiologically typical intraluminal pressure range of 40–50 mmHg, [15,17] the rest of our studies were performed with an intraluminal pressure of 40 mmHg.
Figure 1. Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel, at three different intraluminal pressures (20, 40, and 60 mmHg). Flow-induced dilation was significantly greater at 40 mmHg than at 60 mmHg (P < 0.01). Although flow-induced dilation at 20 mmHg was not significantly different than that at 40 mmHg (P = 0.82), a greater range of pressure gradients could be examined at a vessel intraluminal pressure of 40 mmHg than at 20 mmHg, because the lowest downstream pressure was 0 mmHg in our preparation.
Figure 1. Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel, at three different intraluminal pressures (20, 40, and 60 mmHg). Flow-induced dilation was significantly greater at 40 mmHg than at 60 mmHg (P < 0.01). Although flow-induced dilation at 20 mmHg was not significantly different than that at 40 mmHg (P = 0.82), a greater range of pressure gradients could be examined at a vessel intraluminal pressure of 40 mmHg than at 20 mmHg, because the lowest downstream pressure was 0 mmHg in our preparation.
Figure 1. Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel, at three different intraluminal pressures (20, 40, and 60 mmHg). Flow-induced dilation was significantly greater at 40 mmHg than at 60 mmHg (P < 0.01). Although flow-induced dilation at 20 mmHg was not significantly different than that at 40 mmHg (P = 0.82), a greater range of pressure gradients could be examined at a vessel intraluminal pressure of 40 mmHg than at 20 mmHg, because the lowest downstream pressure was 0 mmHg in our preparation.
×
Endothelial Dependence of Flow-induced Vasodilation
Additional vessels were equilibrated at 37 [degree sign]C in Krebs solution containing 10 [micro sign]M of the NO synthase inhibitor L-NNA, 10 [micro sign]M of the cyclooxygenase inhibitor indomethacin, or both. The Delta P-diameter relation was obtained as noted before and the percentage relaxation from constriction with U46619 was calculated. Viability of the vessels was tested as noted before.
Additional vessels were denuded of the endothelium by passing a piece of human hair through the lumen of the artery. [13] The Delta P-diameter relation was then obtained as noted above and the percentage relaxation from constriction with U46619 was calculated. Viability of the vessels was tested as above. These endothelium-denuded vessels showed no dilation in response to 10 [micro sign]M adenosine diphosphate.
To determine the effect of NO scavenging by hemoglobin in blood, blood was aspirated from the apex of the heart into a syringe containing heparin (final concentration, 333 U/ml) before the heart was removed. The hemoglobin content of the blood collected was measured using a 482 Co-Oximeter (Instrument Laboratory Co., Lexington, MA). The lumen of the isolated vessel was filled with either heparinized Krebs solution, heparinized blood, or heparinized blood diluted with Krebs solution. In all these solutions, the concentration of heparin was 333 U/ml, which effectively prevented blood coagulation in micropipettes. Extraluminally the vessel was bathed in Krebs solution. After equilibration of each vessel at 37 [degree sign]C and preconstriction with U46619 1 [micro sign]M, the Delta P-diameter relation was obtained as noted before. Viability of the vessel was tested as described here before.
Effect of Volatile Anesthetics
To determine the effect of volatile anesthetics, the Delta P-diameter relations of additional vessels were obtained in the presence of 1 or 2 MAC isoflurane (1 MAC = approximately 1.2%)[18] or 1 or 2 MAC halothane (1 MAC = approximately 0.9%)[18] and compared with the relation obtained with endothelium-intact control. After each vessel was equilibrated at 37 [degree sign]C for 30 min in the vessel chamber and preconstricted with U46619 1 [micro sign]M, the vessel was subjected to the anesthetic by adding the anesthetic to the 95% oxygen and 5% carbon dioxide mixture and bubbling the Krebs buffer solution using an in-line bubble-through vaporizer. In a preliminary experiment using gas chromatography, we determined that isoflurane and halothane reached steady state concentrations after introduction in the vessel chamber in <10 and 15 min, respectively. The anesthetic content in the gas mixture was monitored continuously using a Rascal II Gas Analyzer (Ohmeda, Salt Lake City, UT) that was previously calibrated to industrial standards. In a previous report [19] we showed by gas chromatographic analysis that in our experimental preparation the millimolar concentration and partial pressure of isoflurane or halothane in the vessel chamber reflected its concentration in the gas mixture bubbled into the buffer solution.
No significant change in internal diameter of the U46619-preconstricted vessel was noted after steady state concentrations of 1 or 2 MAC isoflurane were obtained. In contrast, there was mild (10–15%) dilation of the U46619-preconstricted vessel after steady state concentrations of halothane were obtained. The diameter obtained after U46619 and either isoflurane or halothane (or neither anesthetic in case of a control vessel) was considered as the constricted diameter.
At least 10 or 15 min after introduction of isoflurane or halothane, respectively, the Delta P - diameter relation was obtained as noted before. At the end of each vessel run, the anesthetic was discontinued and viability of the vessel was tested as noted before.
In addition, the Delta P-diameter relation was determined in the presence of either 2 MAC isoflurane or 2 MAC halothane for vessels pretreated with either 10 [micro sign]M L-NNA or 10 [micro sign]M indomethacin. Viability of these vessels was tested as noted before.
Statistical Analysis
Each animal contributed no more than one vessel to any one experimental group; therefore, n for each group represents the number of animals and the number of vessels. All data are presented as mean +/- SD.
Whether there is a Delta P-dependent dilation of the vessels was tested by one-way analysis of variance (with Scheffe's linear contrast). The effect of an intervention such as endothelial denudation or pretreatment of the vessel with L-NNA on the Delta P-diameter relation was evaluated by two-way analysis of variance with a repeated measures factor, with the post hoc Neuman-Keuls test for between-groups comparison and stratified z tests to identify the gradients in which the differences in responses were significant. Similarly, the effect of anesthetics on the Delta P-diameter relationship was evaluated by a two-way analysis of variance with a repeated-measures factor. The correlation between the flows measured and the pressure gradients was assessed by simple linear regression. Significance was considered as P < 0.05. All statistics were calculated using True Epistat software (Epistat Services, Richardson, TX).
Results
Endothelial Dependence of Flow-induced Dilation
The control coronary microvessels (n = 7; baseline size, 103 +/- 6 [micro sign]m [mean +/- SD]) demonstrated Delta P-dependent dilation (P < 0.001). This effect of Delta P was attenuated by either pretreatment of the vessels with L-NNA (P < 0.001; n = 8; size, 94 +/- 8 [micro sign]m) or indomethacin (P < 0.001; n = 5; size, 97 +/- 11 [micro sign]m) and completely abolished by pretreatment with both L-NNA and indomethacin (P < 0.001; n = 6; size, 111 +/- 8 [micro sign]m) or by endothelial denudation (P < 0.001; n = 5; size, 90 +/- 10 [micro sign]m). With endothelial denudation, there was actually mild constriction of the vessels at high pressure gradients (Figure 2).
Figure 2. Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel. Control vessels showed Delta P-dependent dilation (P < 0.001). (A) This effect was attenuated by either pretreatment of the vessels with the nitric oxide synthase inhibitor NG-nitro-L-arginine(L-NNA) or the cyclooxygenase inhibitor indomethacin and completely abolished either in the presence of both L-NNA and indomethacin, or (B) with endothelial denudation (P < 0.001 each). *P < 0.05 versus control.
Figure 2. Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel. Control vessels showed Delta P-dependent dilation (P < 0.001). (A) This effect was attenuated by either pretreatment of the vessels with the nitric oxide synthase inhibitor NG-nitro-L-arginine(L-NNA) or the cyclooxygenase inhibitor indomethacin and completely abolished either in the presence of both L-NNA and indomethacin, or (B) with endothelial denudation (P < 0.001 each). *P < 0.05 versus control.
Figure 2. Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel. Control vessels showed Delta P-dependent dilation (P < 0.001). (A) This effect was attenuated by either pretreatment of the vessels with the nitric oxide synthase inhibitor NG-nitro-L-arginine(L-NNA) or the cyclooxygenase inhibitor indomethacin and completely abolished either in the presence of both L-NNA and indomethacin, or (B) with endothelial denudation (P < 0.001 each). *P < 0.05 versus control.
×
The addition of heparin to the Krebs solution bathing the lumen of the vessels (n = 7; size, 99 +/- 6 [micro sign]m) mildly enhanced the dilatory response to increasing Delta P (P < 0.01;Figure 3A), consistent with the previously reported endothelium-dependent dilatory effect of heparin. [20] Blood in the lumen attenuated the dilatory response to increasing Delta P, in a hemoglobin concentration-dependent manner (P < 0.001;Figure 3B). (Blood in the lumen: n = 7; size, 94 +/- 15 [micro sign]m; hemoglobin, 11.1 +/- 0.2 g/dl. Blood diluted with Krebs solution in the lumen: n = 7; size, 101 +/- 5 [micro sign]m; hemoglobin, 5.6 +/- 0.1 g/dl).
Figure 3. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel when the perfusate was Krebs solution or heparinized Krebs solution. With heparinization, the Delta P-produced, flow-induced dilation was enhanced (P < 0.01). *P < 0.05 versus Krebs solution as the perfusate. (B) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel with different perfusates. Flow-induced dilation was attenuated as the hemoglobin concentration of the perfusate was increased (P < 0.001). *P < 0.05 versus heparinized Krebs solution as the perfusate. +P < 0.05 versus diluted heparinized blood as the perfusate.
Figure 3. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel when the perfusate was Krebs solution or heparinized Krebs solution. With heparinization, the Delta P-produced, flow-induced dilation was enhanced (P < 0.01). *P < 0.05 versus Krebs solution as the perfusate. (B) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel with different perfusates. Flow-induced dilation was attenuated as the hemoglobin concentration of the perfusate was increased (P < 0.001). *P < 0.05 versus heparinized Krebs solution as the perfusate. +P < 0.05 versus diluted heparinized blood as the perfusate.
Figure 3. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel when the perfusate was Krebs solution or heparinized Krebs solution. With heparinization, the Delta P-produced, flow-induced dilation was enhanced (P < 0.01). *P < 0.05 versus Krebs solution as the perfusate. (B) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel with different perfusates. Flow-induced dilation was attenuated as the hemoglobin concentration of the perfusate was increased (P < 0.001). *P < 0.05 versus heparinized Krebs solution as the perfusate. +P < 0.05 versus diluted heparinized blood as the perfusate.
×
Effect of Volatile Anesthetics on Flow-induced Dilation
Flow-induced dilation of rat coronary vessels was attenuated by isoflurane in a concentration-dependent manner (P < 0.001;Figure 4A). (1 MAC isoflurane: n = 7; size, 82 +/- 13 [micro sign]m. 2 MAC isoflurane: n = 6; size, 100 +/- 5 [micro sign]m). After pretreatment of the vessels with 10 [micro sign]M L-NNA, 2 MAC isoflurane attenuated FID even further (P < 0.01; n = 6; size, 104 +/- 1 [micro sign]m;Figure 4B), indicating that isoflurane was attenuating dilation as a result of an L-NNA-insensitive agent such as a prostanoid. After pretreatment of the vessels with 10 [micro sign]M indomethacin, 2 MAC isoflurane attenuated FID even further (P < 0.05; n = 5; size, 107 +/- 8 [micro sign]m;Figure 4C), indicating that isoflurane was also attenuating dilation as a result of an indomethacin-insensitive agent such as NO.
Figure 4. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel in the presence of different concentrations of isoflurane. Isoflurane attenuated Delta P-produced, flow-induced dilation in a concentration-dependent manner (P < 0.001). *P < 0.05 versus control. +P < 0.05 versus 1 minimum alveolar concentration (MAC) isoflurane. (B) Even after pretreatment of vessels with N (G-nitro-L-arginine)(L-NNA), 2 MAC isoflurane attenuated flow-induced dilation even further (P < 0.01), indicating that isoflurane attenuated dilation as a result of an L-NNA-insensitive agent, most likely a prostanoid. *P < 0.05 between vessels pretreated with L-NNA, whose flow-induced dilation was measured in the presence or absence of 2 MAC isoflurane. (C) Even after pretreatment of vessels with indomethacin, 2 MAC isoflurane attenuated flow-induced dilation even further (P < 0.05), indicating that isoflurane attenuated dilation because of an indomethacin-insensitive agent, most likely nitric oxide. *P < 0.05 between vessels pretreated with indomethacin. The flow-induced dilation of indomethacin was measured in the presence or absence of 2 MAC isoflurane.
Figure 4. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel in the presence of different concentrations of isoflurane. Isoflurane attenuated Delta P-produced, flow-induced dilation in a concentration-dependent manner (P < 0.001). *P < 0.05 versus control. +P < 0.05 versus 1 minimum alveolar concentration (MAC) isoflurane. (B) Even after pretreatment of vessels with N (G-nitro-L-arginine)(L-NNA), 2 MAC isoflurane attenuated flow-induced dilation even further (P < 0.01), indicating that isoflurane attenuated dilation as a result of an L-NNA-insensitive agent, most likely a prostanoid. *P < 0.05 between vessels pretreated with L-NNA, whose flow-induced dilation was measured in the presence or absence of 2 MAC isoflurane. (C) Even after pretreatment of vessels with indomethacin, 2 MAC isoflurane attenuated flow-induced dilation even further (P < 0.05), indicating that isoflurane attenuated dilation because of an indomethacin-insensitive agent, most likely nitric oxide. *P < 0.05 between vessels pretreated with indomethacin. The flow-induced dilation of indomethacin was measured in the presence or absence of 2 MAC isoflurane.
Figure 4. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel in the presence of different concentrations of isoflurane. Isoflurane attenuated Delta P-produced, flow-induced dilation in a concentration-dependent manner (P < 0.001). *P < 0.05 versus control. +P < 0.05 versus 1 minimum alveolar concentration (MAC) isoflurane. (B) Even after pretreatment of vessels with N (G-nitro-L-arginine)(L-NNA), 2 MAC isoflurane attenuated flow-induced dilation even further (P < 0.01), indicating that isoflurane attenuated dilation as a result of an L-NNA-insensitive agent, most likely a prostanoid. *P < 0.05 between vessels pretreated with L-NNA, whose flow-induced dilation was measured in the presence or absence of 2 MAC isoflurane. (C) Even after pretreatment of vessels with indomethacin, 2 MAC isoflurane attenuated flow-induced dilation even further (P < 0.05), indicating that isoflurane attenuated dilation because of an indomethacin-insensitive agent, most likely nitric oxide. *P < 0.05 between vessels pretreated with indomethacin. The flow-induced dilation of indomethacin was measured in the presence or absence of 2 MAC isoflurane.
×
On the other hand, 2 MAC halothane enhanced the FID of coronary vessels (P < 0.05; n = 5; size, 94 +/- 14 [micro sign]m). Halothane at 1 MAC had no significant effect on FID (P = 0.52; n = 6; size, 100 +/- 14 [micro sign]m;Figure 5A). After pretreatment of the vessels with 10 [micro sign]M L-NNA, 2 MAC halothane did not enhance FID any further (P = 0.40; n = 6; size, 102 +/- 10 [micro sign]m;Figure 5B), indicating that halothane-mediated enhancement of FID was not the result of an L-NNA-insensitive agent such as a prostanoid. However, after pretreatment of the vessels with 10 [micro sign]M indomethacin, 2 MAC halothane enhanced FID (P < 0.05; n = 6; size, 105 +/- 7 [micro sign]m;Figure 5C), indicating that the enhancement may involve an indomethacin-insensitive agent such as NO.
Figure 5. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel in the presence of different concentrations of halothane. Two minimum alveolar concentration (MAC) halothane enhanced flow-induced dilation (P < 0.05), whereas 1 MAC halothane had no significant effect (P = 0.52). *P < 0.05 versus control. (B) After pretreatment of vessels with NG-nitro-L-arginine(L-NNA), 2 MAC halothane did not enhance flow-induced dilation (P = 0.40), indicating that halothane-mediated enhancement of flow-mediated dilation was not caused by an L-NNA-insensitive agent such as a prostanoid. (C) After pretreatment of vessels with indomethacin, 2 MAC halothane enhanced flow-induced dilation even further (P < 0.05), indicating that halothane enhanced dilation as a result of an indomethacin-insensitive agent, most likely nitric oxide. *P < 0.05 between vessels pretreated with indomethacin, whose flow-induced dilation was measured in the presence or absence of 2 MAC halothane.
Figure 5. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel in the presence of different concentrations of halothane. Two minimum alveolar concentration (MAC) halothane enhanced flow-induced dilation (P < 0.05), whereas 1 MAC halothane had no significant effect (P = 0.52). *P < 0.05 versus control. (B) After pretreatment of vessels with NG-nitro-L-arginine(L-NNA), 2 MAC halothane did not enhance flow-induced dilation (P = 0.40), indicating that halothane-mediated enhancement of flow-mediated dilation was not caused by an L-NNA-insensitive agent such as a prostanoid. (C) After pretreatment of vessels with indomethacin, 2 MAC halothane enhanced flow-induced dilation even further (P < 0.05), indicating that halothane enhanced dilation as a result of an indomethacin-insensitive agent, most likely nitric oxide. *P < 0.05 between vessels pretreated with indomethacin, whose flow-induced dilation was measured in the presence or absence of 2 MAC halothane.
Figure 5. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel in the presence of different concentrations of halothane. Two minimum alveolar concentration (MAC) halothane enhanced flow-induced dilation (P < 0.05), whereas 1 MAC halothane had no significant effect (P = 0.52). *P < 0.05 versus control. (B) After pretreatment of vessels with NG-nitro-L-arginine(L-NNA), 2 MAC halothane did not enhance flow-induced dilation (P = 0.40), indicating that halothane-mediated enhancement of flow-mediated dilation was not caused by an L-NNA-insensitive agent such as a prostanoid. (C) After pretreatment of vessels with indomethacin, 2 MAC halothane enhanced flow-induced dilation even further (P < 0.05), indicating that halothane enhanced dilation as a result of an indomethacin-insensitive agent, most likely nitric oxide. *P < 0.05 between vessels pretreated with indomethacin, whose flow-induced dilation was measured in the presence or absence of 2 MAC halothane.
×
Discussion
The main findings of this study are as follows. First, the FID of rat coronary microvessels is endothelium dependent and appears mediated by both NO and a prostanoid(s). Second, as hypothesized, isoflurane attenuates FID of rat coronary microvessels. This attenuation appears to involve attenuation of both NO- and prostanoid-mediated dilation. Third, halothane does not have the same effect, but at a high concentration it enhances FID.
Critique of Our Vessel Preparation
Our preparation is a microvessel chamber video detection system [14,15] adapted for administration of volatile anesthetics into the chamber. By matching the pipettes for size and resistance and by altering the heights of the fluid reservoirs connected to the pipettes in opposite directions simultaneously, we could alter pressure gradients and thus flow without altering midpoint luminal pressure in the vessel, thus avoiding myogenic responses. [14,15] Functional symmetry of the setup was further proved by showing that FID did not depend on the direction of the flow.
The flows measured in our preparation were somewhat greater than those reported by Kuo et al. [15] Erythrocyte velocity in turtle and canine coronary arterioles ([approximately] 10–40 [micro sign]m diameter) approaches 3.5 mm/s during diastole but decreases to <2 mm/s during systole. [21] In rat skeletal muscle arterioles, erythrocyte velocity ranges from [approximately] 5–30 mm/s and blood flow from 1 - 170 nl/s, with the numbers increasing in the proximal arterioles. [22] Our vessels are distal resistance arteries in which the flow would be expected to be greater than in the distal arterioles (40–80 [micro sign]m) examined by Kuo et al. [15] Therefore the flows we measured ([approximately] 50–250 nl/s) appear to be within the physiologic range.
Comparison with Previous Studies
Flow-induced dilation has been described in many species, including cats, [23] pigs, [15] and humans. [24] The first demonstration in resistance coronary arteries was by Kuo et al. [15] Our findings of FID in rats corroborates Kuo et al.'s findings in pigs. The importance of endothelium in mediating FID has been recognized nearly uniformly. Removal of endothelium has either abolished the response [15,25] or converted it to one of mild constriction. [26] Even Bevan et al., [27] who reported that FID of rabbit ear arteries persisted after endothelium removal, noted that the response was enhanced in the presence of the endothelium. Our finding of abolished FID in the endothelium-denuded vessels or vessels pretreated with L-NNA and indomethacin are consistent with the results of the previous studies.
We found that in rat subepicardial arteries both NO and prostanoids are effective in mediating EDD in response to flow increases. Although one or both of these mediators may be important in FID, the exact nature of the mediator(s) may depend on the species, the tissue type, and the vessel size and function. Whereas in porcine coronary arterioles FID appears to occur via NO and is not affected by the cyclooxygenase inhibitor indomethacin, [28] inhibitors of NO synthesis had no effect on FID of epicardial coronary arteries in dogs [29] and humans. [30] In canine femoral segments, both prostanoids and NO played roles in FID, [31] whereas in rat cremaster muscle arterioles prostanoids, but not NO, may be important. [14] 
Changing the perfusate from Krebs solution to blood in our experiment not only increased the viscosity of the solution as a result of various components, such as proteins and cells, but also introduced hemoglobin in the erythrocytes. Increased viscosity would tend to increase shear stress at any given flow and enhance FID. [2] However, under conditions of high oxygen tension such as in our preparation, hemoglobin scavenges NO [32] and would be expected to attenuate the NO-mediated components of FID. The net effect of using blood in our preparation was to attenuate FID. Under conditions of lower oxygen tension, when hemoglobin does not also scavenge NO, blood might not attenuate FID as much.
The Effect of Volatile Anesthetics
Using rat subepicardial resistance arteries, we showed previously that isoflurane and halothane attenuate agonist-induced EDD and that whereas the attenuating action of halothane appears limited to the endothelial receptor of the agonist, the effect of isoflurane may include an action on the smooth muscle guanylate cyclase. [5] Based on these findings, isoflurane was hypothesized to attenuate the effect of NO, whether produced by agonist stimulation or flow. Indeed we found that isoflurane attenuates FID of subepicardial microvessels due to an indomethacin-insensitive product (most likely NO).
Furthermore, isoflurane may also have an effect on prostanoid-mediated FID. Vasodilatory prostanoids activate vascular smooth muscle adenylate cyclase, increasing cyclic adenosine monophosphate and thereby producing relaxation. [33] Isoflurane attenuates cyclic adenosine monophosphate-mediated vasodilation [34] and therefore may be expected to attenuate prostanoid-mediated vasodilation, as we saw in our current study. Besides attenuating NO- and prostanoid-mediated dilation, isoflurane has multiple procontractile, antidilatory mechanisms in subepicardial arteries, such as enhancement of protein kinase C activity [35] and generation of oxygen-derived free radicals. [36] 
On the other hand, halothane, whose effect on the NO-cyclic guanosine monophosphate pathway is limited to the endothelial agonist-receptor level in rat subepicardial microvessels, [5] does not attenuate FID, which produces NO in an agonist receptor-independent mechanism. Rather, at a high concentration halothane enhances the NO-mediated component of FID. Such an enhancement may involve either enhanced transduction of increased shear stress at the endothelial cell level or enhanced response to NO after its synthesis. Because halothane does not enhance vasodilation from agonist-induced production of NO, [3–5,9–12] the anesthetic may be hypothesized to enhance transduction of shear stress.
In our preparation, halothane had no effect on prostanoid-mediated FID. In the only study that examined the relation between halothane and endothelial prostacyclin production, Loeb et al. [37] found in cultured bovine endothelial cells that halothane attenuates prostacyclin production stimulated by bradykinin but not by adenosine triphosphate or melittin. Halothane may have an attenuating effect on one pathway of endothelial prostacyclin production, but not others, depending on the animal species, vessel type, and type of stimulation.
Possible Implications of These Data
Flow-induced dilation is an important determinant of myocardial blood flow distribution, helping to match blood flow to tissue needs. [1] It may also play a role in the initial phase of collateral circulation development, adaptation of the arterial bed to altered blood viscosity, and modulation of vasoconstrictive influences. [3,38] Impairment of FID has been associated with atherosclerosis and coronary artery disease. [39] In such other pathologic states as hypercholesterolemia [40] and reperfusion injury, [41] in which the endothelium is dysfunctional, FID might be impaired as well.
However, the fact that isoflurane attenuates FID of subepicardial microvessels does not necessarily imply that this anesthetic has an adverse effect on myocardial blood flow distribution. First, any extrapolation from our study should be tempered by the fact that our investigation is but one in vitro study in an experimental animal species under conditions of hyperoxia and no proteins. However, rat models of coronary circulation have been useful extrapolations of human circulation. [42,43] Second, FID is only one of the determinants of myocardial blood flow distribution. The effect of isoflurane on other determinants should also be considered. Myogenic responses in subepicardial microvessels are well preserved or enhanced with isoflurane. [44] In addition, the direct vasomotor effect of isoflurane in a collateral-dependent circulation may favor redistribution of blood flow to the collateral-dependent region, thus tending to prevent ischemia. [45] The net in vivo effect of isoflurane on myocardial blood flow distribution may result from many component effects.
Similarly, the net in vivo effect of halothane on myocardial blood flow distribution should be assessed in terms of several component effects. Although halothane preserves or enhances FID, it inhibits myogenic responses. [44] In vivo, the predominant effect of halothane on myocardial blood flow may be secondary to myocardial metabolic depression and a corresponding decrease in flow. [19] 
In conclusion, we found that FID occurs in rat subepicardial resistance arteries and that this phenomenon is endothelium-dependent and mediated by both NO and a prostanoid. Further, the volatile anesthetics isoflurane and halothane have opposite effects on FID, with the former attenuating it and the latter enhancing it. Our results may have implications for the effect of the anesthetics on myocardial blood flow distribution.
REFERENCES
Jones CJH, Kuo L, Davis MJ, Chilian WM: Myogenic and flow-dependent control mechanisms in the coronary microcirculation. Basic Res Cardiol 1993; 88:2-10
Melkumyants AM, Balashov SA, Khayutin VM: Control of arterial lumen by shear stress on endothelium. News Physiol Sci 1995; 10:204-10
Muldoon SM, Hart JL, Bowen KA, Freas W: Attenuation of endothelium-mediated vasodilation by halothan. Anesthesiology 1988; 68:31-7
Uggeri MJ, Proctor GJ, Johns RA: Halothane, enflurane, and isoflurane attenuate both receptor- and non-receptor-mediated EDRF production in rat thoracic aorta. Anesthesiology 1992; 76:1012-7
Park KW, Dai HB, Lowenstein E, Darvish A, Sellke FW: Isoflurane and halothane attenuate endothelium-dependent vasodilation in rat coronary microvessels. Anesth Analg 1997; 84:278-84
Akata T, Nakashima M, Kodama K, Boyle WA, III, Takahashi S: Effects of volatile anesthestics on acetylcholine-induced relaxation in the rabbit mesenteric resistance artery. Anesthesiology 1995; 82:188-204
Murray PA, Fehr DM, Chen BB, Rock P, Esther JW, Desai PM, Nyhan DP: Differential effects of general anesthesia on cGMP-mediated pulmonary vasodilation. J Appl Physiol 1992; 73:721-7
Sigmon DH, Florentino-Pineda I, Van Dyke RA, Beierwaltes WH: Halothane impairs the hemodynamic influence of endothelium-derived nitric oxide. Anesthesiology 1995; 82:135-43
Johns RA, Tichotsky A, Muro M, Spaeth JP, Le Cras TD, Rengasamy A: Halothane and isoflurane inhibit endothelium-derived relaxing factor-dependent cyclic guanosine monophosphate accumulation in endothelial cell-vascular smooth muscle co-cultures independent of an effect on guanylyl cyclase activation. Anesthesiology 1995; 83:823-34
Zuo Z, Tichotsky A, Johns RA: Halothane and isoflurane inhibit vasodilation due to constitutive but not inducible nitric oxide synthase. Anesthesiology 1996; 84:1156-65
Hart JL, Jing M, Bina S, Freas W, Van Dyke RA, Muldoon SM: Effects of halothane on EDRF/cGMP-mediated vascular smooth muscle relaxations. Anesthesiology 1995; 79:323-31
Jing M, Bina S, Verma A, Hart JL, Muldoon SM: Effects of halothane and isoflurane on carbon monoxide-induced relaxations in the rat aorta. Anesthesiology 1996; 85:347-54
Park KW, Dai HB, Lowenstein E, Darvish A, Sellke FW: Heterogeneous vasomotor effect of isoflurane on rabbit coronary microvessels. Anesthesiology 1994; 81:1190-7
Koller A, Sun D, Kaley G: Role of shear stress and endothelial prostaglandins in flow- and viscosity-induced dilation of arterioles in vitro. Circ Res 1993; 72:1276-84
Kuo L, Davis MJ, Chilian WM: Endothelium-dependent, flow-induced dilation of isolated coronary arterioles. Am J Physiol 1990; 259:H1063-70
Park KW, Dai HB, Lowenstein E, Sellke FW: Propofol-associated dilation of rat distal coronary arteries is mediated by multiple agents, including endothelium-derived nitric oxide. Anesth Analg 1995; 81:1191-6
Chilian WM, Eastham CL, Marcus ML: Microvascular distribution of coronary vascular resistance in beating left ventricle. Am J Physiol 1986; 251:H779-88
Vitez TS, White PF, Eger EI II: Effects of hypothermia on halothane MAC and isoflurane MAC in the rat. Anesthesiology 1974; 41:80-1
Park KW, Dai HB, Lowenstein E, Sellke FW: Vasomotor responses of rat coronary arteries to isoflurane and halothane depend of pre-exposure tone and vessel size. Anesthesiology 1995; 83:1323-30
Li JM, Hajarizadeh H, La Rosa CA, Rohrer MJ, Vander Salm TJ, Cutler BS: Heparin and protamine stimulate the production of nitric oxide. J Cardiovasc Surg 1996; 37:445-52
Tillmanns H, Ikeda S, Hansen H, Sarma JSM, Fauvel J-M, Bing RJ. Microcirculation in the ventricle of the dog and turtle. Circ Res 1974; 34:561-9
Meininger GA, Mack CA, Fehr KL, Bohlen HG. Myogenic vasoregulation overrides local metabolic control in resting rat skeletal muscle. Circ Res 1987; 60:861-70
Schretzenmayr A: Uber kreislaufregulatorische Vorgange an den groBen Arterien bei der Muskelarbeit. Pflugers Arch 1933; 232:743-8
Drexler H, Zeiher AM, Wollschlager H, Meinertz T, Just H, Bonzel T: Flow-dependent coronary artery dilatation in humans. Circulation 1989; 80:466-74
Pohl U, Holtz J, Busse R, Bassenge E: Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 1986; 8:37-44
Hull SS Jr, Kaiser L, Jaffe MD, Sparks HV Jr: Endothelium-dependent flow-induced dilation of canine femoral and saphenous arteries. Blood Vessels 1986; 23:183-98
Bevan JA, Joyce EH, Wellman GC: Flow-dependent dilation in a resistance artery still occurs after endothelium removal. Circ Res 1988; 63:980-5
Kuo L, Chancellor JD: Adenosine potentiates flow-induced dilation of coronary arterioles by activating KATPchannels in endothelium. Am J Physiol 1995; 269:H541-9
Canty JM, Schwartz JS: Nitric oxide mediates flow-dependent epicardial coronary vasodilation to changes in pulse frequency but not mean flow in conscious dogs. Circulation 1994; 89:375-84
Shiode N, Morshima N, Nakayama K, Yamagata T, Matsuura H, Kajiyama G: Flow-mediated vasodilation of human epicardial coronary arteries: Effect of inhibition of nitric oxide synthesis. J Am Coll Cardiol 1996; 27:304-10
Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986; 250:H1145-9
Jia L, Bonaventura C, Bonaventura J, Stamler JS: S-nitrosohaemoglobin: A dynamic activity of blood involved in vascular control. Nature 1996; 380:221-6
Griffith TM, Lewis MJ, Newby AC, Henderson AH: Endothelium-derived relaxing factor. J Am Coll Cardiol 1988; 12:797-806
Park KW, Dai H, Lowenstein E, Darvish A, Sellke FW: Isoflurane attenuates cAMP-mediated vasodilation in rat microvessels. Circulation 1995; 92(suppl II):II423-7
Park KW, Dai HB, Lowenstein E, Sellke FW: Protein kinase C-induced contraction is inhibited by halothane but enhanced by isoflurane in rat coronary arteries. Anesth Analg 1996; 83:286-90
Park KW, Dai HB, Lowenstein E, Darvish A, Sellke FW: Oxygen-derived free radicals mediate isoflurane-induced vasoconstriction of rabbit coronary resistance arteries. Anesth Analg 1995; 80:1163-7
Loeb AL, O'Brien DK, Longnecker DE: Halothane inhibits bradykinin-stimulated prostacyclin production in endothelial cells. Anesthesiology 1994; 81:931-8
Lamping KG, Dole WP: Flow-mediated dilation attenuates constriction of large coronary arteries to serotonin. Am J Physiol 1988; 255:H1317-24
Cox DA, Vita JA, Treasure CB, Fish RD, Alexander RW, Ganz P, Selwyn AP: Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation 1989; 80:458-65
Shimokawa H, Kim P, Vanhoutte PM: Endothelium-dependent relaxation to aggregating platelets in isolated basilar arteries of control and hypercholesterolemic pigs. Circ Res 1988; 63:604-12
Sellke FW, Shafique T, Schoen FJ, Weintraub RM: Impaired endothelium-dependent coronary microvascular relaxation after cold potassium cardioplegia and reperfusion. J Thorac Cardiovasc Surg 1993; 105:52-8
Minamino T, Kurihara H, Takahashi M, Shimada K, Maemura K, Oda H, Ishikawa T, Uchiyama T, Tanzawa K, Yazaki Y: Endothelial-converting enzyme expression in the rat vascular injury model and human coronary atherosclerosis. Circulation 1997; 95:221-30
Marshall I, Al-Kazwini SJ, Roberts PM, Shepperson NB, Adams M, Craig RK: Cardiovascular effects of human and rat CGRP compared in the rat and other species. Eur J Pharmacol 1986; 123:207-16
Park KW, Dai HB, Lowenstein E, Sellke FW: Steady-state myogenic response of rat coronary microvessels is preserved by isoflurane but not by halothane. Anesth Analg 1996; 82:969-74
Park KW, Lowenstein E, Dai HB, Lopez JJ, Stamler A, Simons M, Sellke FW: Direct vasomotor effects of isoflurane in subepicardial resistance vessels from collateral-dependent and normal coronary circulation of pigs. Anesthesiology 1996; 85:584-91
Figure 1. Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel, at three different intraluminal pressures (20, 40, and 60 mmHg). Flow-induced dilation was significantly greater at 40 mmHg than at 60 mmHg (P < 0.01). Although flow-induced dilation at 20 mmHg was not significantly different than that at 40 mmHg (P = 0.82), a greater range of pressure gradients could be examined at a vessel intraluminal pressure of 40 mmHg than at 20 mmHg, because the lowest downstream pressure was 0 mmHg in our preparation.
Figure 1. Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel, at three different intraluminal pressures (20, 40, and 60 mmHg). Flow-induced dilation was significantly greater at 40 mmHg than at 60 mmHg (P < 0.01). Although flow-induced dilation at 20 mmHg was not significantly different than that at 40 mmHg (P = 0.82), a greater range of pressure gradients could be examined at a vessel intraluminal pressure of 40 mmHg than at 20 mmHg, because the lowest downstream pressure was 0 mmHg in our preparation.
Figure 1. Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel, at three different intraluminal pressures (20, 40, and 60 mmHg). Flow-induced dilation was significantly greater at 40 mmHg than at 60 mmHg (P < 0.01). Although flow-induced dilation at 20 mmHg was not significantly different than that at 40 mmHg (P = 0.82), a greater range of pressure gradients could be examined at a vessel intraluminal pressure of 40 mmHg than at 20 mmHg, because the lowest downstream pressure was 0 mmHg in our preparation.
×
Figure 2. Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel. Control vessels showed Delta P-dependent dilation (P < 0.001). (A) This effect was attenuated by either pretreatment of the vessels with the nitric oxide synthase inhibitor NG-nitro-L-arginine(L-NNA) or the cyclooxygenase inhibitor indomethacin and completely abolished either in the presence of both L-NNA and indomethacin, or (B) with endothelial denudation (P < 0.001 each). *P < 0.05 versus control.
Figure 2. Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel. Control vessels showed Delta P-dependent dilation (P < 0.001). (A) This effect was attenuated by either pretreatment of the vessels with the nitric oxide synthase inhibitor NG-nitro-L-arginine(L-NNA) or the cyclooxygenase inhibitor indomethacin and completely abolished either in the presence of both L-NNA and indomethacin, or (B) with endothelial denudation (P < 0.001 each). *P < 0.05 versus control.
Figure 2. Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel. Control vessels showed Delta P-dependent dilation (P < 0.001). (A) This effect was attenuated by either pretreatment of the vessels with the nitric oxide synthase inhibitor NG-nitro-L-arginine(L-NNA) or the cyclooxygenase inhibitor indomethacin and completely abolished either in the presence of both L-NNA and indomethacin, or (B) with endothelial denudation (P < 0.001 each). *P < 0.05 versus control.
×
Figure 3. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel when the perfusate was Krebs solution or heparinized Krebs solution. With heparinization, the Delta P-produced, flow-induced dilation was enhanced (P < 0.01). *P < 0.05 versus Krebs solution as the perfusate. (B) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel with different perfusates. Flow-induced dilation was attenuated as the hemoglobin concentration of the perfusate was increased (P < 0.001). *P < 0.05 versus heparinized Krebs solution as the perfusate. +P < 0.05 versus diluted heparinized blood as the perfusate.
Figure 3. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel when the perfusate was Krebs solution or heparinized Krebs solution. With heparinization, the Delta P-produced, flow-induced dilation was enhanced (P < 0.01). *P < 0.05 versus Krebs solution as the perfusate. (B) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel with different perfusates. Flow-induced dilation was attenuated as the hemoglobin concentration of the perfusate was increased (P < 0.001). *P < 0.05 versus heparinized Krebs solution as the perfusate. +P < 0.05 versus diluted heparinized blood as the perfusate.
Figure 3. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel when the perfusate was Krebs solution or heparinized Krebs solution. With heparinization, the Delta P-produced, flow-induced dilation was enhanced (P < 0.01). *P < 0.05 versus Krebs solution as the perfusate. (B) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel with different perfusates. Flow-induced dilation was attenuated as the hemoglobin concentration of the perfusate was increased (P < 0.001). *P < 0.05 versus heparinized Krebs solution as the perfusate. +P < 0.05 versus diluted heparinized blood as the perfusate.
×
Figure 4. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel in the presence of different concentrations of isoflurane. Isoflurane attenuated Delta P-produced, flow-induced dilation in a concentration-dependent manner (P < 0.001). *P < 0.05 versus control. +P < 0.05 versus 1 minimum alveolar concentration (MAC) isoflurane. (B) Even after pretreatment of vessels with N (G-nitro-L-arginine)(L-NNA), 2 MAC isoflurane attenuated flow-induced dilation even further (P < 0.01), indicating that isoflurane attenuated dilation as a result of an L-NNA-insensitive agent, most likely a prostanoid. *P < 0.05 between vessels pretreated with L-NNA, whose flow-induced dilation was measured in the presence or absence of 2 MAC isoflurane. (C) Even after pretreatment of vessels with indomethacin, 2 MAC isoflurane attenuated flow-induced dilation even further (P < 0.05), indicating that isoflurane attenuated dilation because of an indomethacin-insensitive agent, most likely nitric oxide. *P < 0.05 between vessels pretreated with indomethacin. The flow-induced dilation of indomethacin was measured in the presence or absence of 2 MAC isoflurane.
Figure 4. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel in the presence of different concentrations of isoflurane. Isoflurane attenuated Delta P-produced, flow-induced dilation in a concentration-dependent manner (P < 0.001). *P < 0.05 versus control. +P < 0.05 versus 1 minimum alveolar concentration (MAC) isoflurane. (B) Even after pretreatment of vessels with N (G-nitro-L-arginine)(L-NNA), 2 MAC isoflurane attenuated flow-induced dilation even further (P < 0.01), indicating that isoflurane attenuated dilation as a result of an L-NNA-insensitive agent, most likely a prostanoid. *P < 0.05 between vessels pretreated with L-NNA, whose flow-induced dilation was measured in the presence or absence of 2 MAC isoflurane. (C) Even after pretreatment of vessels with indomethacin, 2 MAC isoflurane attenuated flow-induced dilation even further (P < 0.05), indicating that isoflurane attenuated dilation because of an indomethacin-insensitive agent, most likely nitric oxide. *P < 0.05 between vessels pretreated with indomethacin. The flow-induced dilation of indomethacin was measured in the presence or absence of 2 MAC isoflurane.
Figure 4. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel in the presence of different concentrations of isoflurane. Isoflurane attenuated Delta P-produced, flow-induced dilation in a concentration-dependent manner (P < 0.001). *P < 0.05 versus control. +P < 0.05 versus 1 minimum alveolar concentration (MAC) isoflurane. (B) Even after pretreatment of vessels with N (G-nitro-L-arginine)(L-NNA), 2 MAC isoflurane attenuated flow-induced dilation even further (P < 0.01), indicating that isoflurane attenuated dilation as a result of an L-NNA-insensitive agent, most likely a prostanoid. *P < 0.05 between vessels pretreated with L-NNA, whose flow-induced dilation was measured in the presence or absence of 2 MAC isoflurane. (C) Even after pretreatment of vessels with indomethacin, 2 MAC isoflurane attenuated flow-induced dilation even further (P < 0.05), indicating that isoflurane attenuated dilation because of an indomethacin-insensitive agent, most likely nitric oxide. *P < 0.05 between vessels pretreated with indomethacin. The flow-induced dilation of indomethacin was measured in the presence or absence of 2 MAC isoflurane.
×
Figure 5. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel in the presence of different concentrations of halothane. Two minimum alveolar concentration (MAC) halothane enhanced flow-induced dilation (P < 0.05), whereas 1 MAC halothane had no significant effect (P = 0.52). *P < 0.05 versus control. (B) After pretreatment of vessels with NG-nitro-L-arginine(L-NNA), 2 MAC halothane did not enhance flow-induced dilation (P = 0.40), indicating that halothane-mediated enhancement of flow-mediated dilation was not caused by an L-NNA-insensitive agent such as a prostanoid. (C) After pretreatment of vessels with indomethacin, 2 MAC halothane enhanced flow-induced dilation even further (P < 0.05), indicating that halothane enhanced dilation as a result of an indomethacin-insensitive agent, most likely nitric oxide. *P < 0.05 between vessels pretreated with indomethacin, whose flow-induced dilation was measured in the presence or absence of 2 MAC halothane.
Figure 5. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel in the presence of different concentrations of halothane. Two minimum alveolar concentration (MAC) halothane enhanced flow-induced dilation (P < 0.05), whereas 1 MAC halothane had no significant effect (P = 0.52). *P < 0.05 versus control. (B) After pretreatment of vessels with NG-nitro-L-arginine(L-NNA), 2 MAC halothane did not enhance flow-induced dilation (P = 0.40), indicating that halothane-mediated enhancement of flow-mediated dilation was not caused by an L-NNA-insensitive agent such as a prostanoid. (C) After pretreatment of vessels with indomethacin, 2 MAC halothane enhanced flow-induced dilation even further (P < 0.05), indicating that halothane enhanced dilation as a result of an indomethacin-insensitive agent, most likely nitric oxide. *P < 0.05 between vessels pretreated with indomethacin, whose flow-induced dilation was measured in the presence or absence of 2 MAC halothane.
Figure 5. (A) Percentage relaxation of the U46619-preconstricted vessel in response to changes in pressure gradients (Delta P) across the vessel in the presence of different concentrations of halothane. Two minimum alveolar concentration (MAC) halothane enhanced flow-induced dilation (P < 0.05), whereas 1 MAC halothane had no significant effect (P = 0.52). *P < 0.05 versus control. (B) After pretreatment of vessels with NG-nitro-L-arginine(L-NNA), 2 MAC halothane did not enhance flow-induced dilation (P = 0.40), indicating that halothane-mediated enhancement of flow-mediated dilation was not caused by an L-NNA-insensitive agent such as a prostanoid. (C) After pretreatment of vessels with indomethacin, 2 MAC halothane enhanced flow-induced dilation even further (P < 0.05), indicating that halothane enhanced dilation as a result of an indomethacin-insensitive agent, most likely nitric oxide. *P < 0.05 between vessels pretreated with indomethacin, whose flow-induced dilation was measured in the presence or absence of 2 MAC halothane.
×